Research Project
10301455
Project Summary This subaward application of the Rutgers Cancer Institute of New Jersey, as an Affiliated Organization (AO) of the North American Star Consortium (NASC), with Salma Jabbour, MD, as the contact PI, will serve to continue the collaboration in early phase clinical trials with multiple renowned institutions. The Rutgers Cancer Institute of New Jersey has an established history of achievement within the ETCTN, with active leadership, dedicated infrastructure, and contributions toward the development and execution of ETCTN- sponsored early phase clinical trials as well as mentorship of Early Career Investigators. Our team will continue to collaborate within the existing infrastructure of the Princess Margaret Cancer Center, LAO of the NASC, which includes accomplished clinical trial programs and investigators from Moffitt Cancer Center, Virginia Commonwealth University-Massey Cancer Center, University of Texas Southwestern Simmons Cancer Center, and Northwestern Lurie Cancer Center. Rutgers Cancer Institute has demonstrated robust performance within the ETCTN for over a decade by leading impactful investigator-initiated trials generated by NCI-funded science and prioritizing the career development of junior faculty. The sustained productivity of the Rutgers Cancer Institute will continue to go forward within the NASC to address the following Specific Aims: 1. To participate and carry out novel phase 1 and phase 2 ETCTN trials through participation in the NASC. 2. To enroll patients on ETCTN trials that require the acquisition of high- quality tumor tissue for biomarker and pharmacodynamic analyses, include pharmacokinetic (PK) endpoints, and closely follow Good Clinical Practice and Human Subject Protection guidelines. 3. To mentor and develop the next generation of investigators in clinical and translational research.
